Home Protein Tyrosine Kinase Trk receptor inhibitor Selitrectinib (LOXO-195) For research use only.

Selitrectinib (LOXO-195)

Synonyms: BAY 2731954

Selitrectinib (LOXO-195, BAY 2731954) is an orally available, highly potent, and selective TRK kinase inhibitor with low nanomolar inhibitory activity against TRKA G595R, TRKC G623R, and TRKA G667C, IC50s ranging from 2.0 to 9.8 nmol/L. It is more than 1,000-fold selective for 98% of non-TRK kinases tested.

Selitrectinib (LOXO-195) Chemical Structure

Selitrectinib (LOXO-195) Chemical Structure

CAS: 2097002-61-2

Selleck's Selitrectinib (LOXO-195) has been cited by 3 publications

Purity & Quality Control

Batch: Purity: 99.92%
99.92

Selitrectinib (LOXO-195) Related Products

Signaling Pathway

Trk receptor Signaling Pathways

Trk receptor Signaling Pathway

Choose Selective Trk receptor Inhibitors

Biological Activity

Description Selitrectinib (LOXO-195, BAY 2731954) is an orally available, highly potent, and selective TRK kinase inhibitor with low nanomolar inhibitory activity against TRKA G595R, TRKC G623R, and TRKA G667C, IC50s ranging from 2.0 to 9.8 nmol/L. It is more than 1,000-fold selective for 98% of non-TRK kinases tested.
Targets
WT TRKA [1]
(Celll-free assay)		 TRKA G595R [1]
(Cell-free assay)		 TRKC G623R [1]
(Cell-free assay)		 WT TRKC [1]
(Cell-free assay)		 TRKC G696A [1]
(Cell-free assay)		 Click to View More Targets
0.6 nM 2 nM 2.3 nM 2.5 nM 2.5 nM
In vitro
In vitro

LOXO-195 potently inhibits diverse activated TRK kinases in vitro. At a concerntration of 1 μM, which is approximately 1,667-fold higher than its IC50 for TRKA (0.6 nmol/L), LOXO-195 is more than 1,000-fold selective for 98% of non-TRK kinases tested (228 individual kinases). LOXO-195 demonstrates potent inhibition of cell proliferation in TRK fusion–containing KM12, CUTO-3, and MO-91 cell lines (IC50 ≤ 5 nmol/L). In contrast, LOXO-195 treatment with concentrations up to 10 μmol/L has no inhibitory effect on the growth of the 84 cell lines that did not contain a TRK fusion[1].
Cell Research Cell lines GON4L-NTRK cells
Concentrations 50 nM
Incubation Time 24 h
Method

Cells were treated with indicated concentration of drug for 24 h.
In Vivo
In vivo

LOXO-195 is effective at reducing phosphorylated TRKA in tumors driven by ΔTRKA. LOXO-195 also causes inhibition of tumor growth relative to vehicle at all doses in four TRKA-dependent tumor models (NIH 3T3 ΔTRKA, ΔTRKA G595R, ΔTRKA G667C, and TPM3-NTRK1 fusion-positive KM12 colorectal cancer cells)[1].
Animal Research Animal Models Mice
Dosages 10 mg/kg
Administration p.o.
NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT04275960 Completed
Solid Tumors Harboring NTRK Fusion
Bayer
 February 28 2020 Phase 1
NCT03215511 Completed
Solid Tumors Harboring NTRK Fusion
Bayer
 July 3 2017 Phase 1

Chemical Information & Solubility

Molecular Weight 380.42 Formula

C20H21FN6O 
CAS No. 2097002-61-2 SDF --
Smiles CC1CCC2=C(C=C(C=N2)F)C3CCCN3C4=NC5=C(C=NN5C=C4)C(=O)N1
Storage (From the date of receipt) 3 years -20°C powder

In vitro
Batch:

DMSO : 38 mg/mL ( (99.88 mM)； Moisture-absorbing DMSO reduces solubility. Please use fresh DMSO.)

Ethanol : 15 mg/mL

Water : Insoluble


Molecular Weight Calculator

In vivo
Batch:

Add solvents to the product individually and in order.


In vivo Formulation Calculator

Preparing Stock Solutions

Molarity Calculator

Mass Concentration Volume Molecular Weight

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Selitrectinib (LOXO-195) | Selitrectinib (LOXO-195) supplier | purchase Selitrectinib (LOXO-195) | Selitrectinib (LOXO-195) cost | Selitrectinib (LOXO-195) manufacturer | order Selitrectinib (LOXO-195) | Selitrectinib (LOXO-195) distributor